Impact of corticosteroid therapy on outcomes of persons with SARS-CoV-2, SARS-CoV, or MERS-CoV infection: a systematic review and meta-analysis

Leukemia

Volumn 34, Issue 6, 2020, Pages 1503-1511

  Li, Huan ^a   Chen, Chongxiang ^a,b   Hu, Fang ^a   Wang, Jiaojiao ^c   Zhao, Qingyu ^a   Gale, Robert Peter ^d   Liang, Yang ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b GUANGZHOU MEDICAL UNIVERSITY   (China)

^c FUJIAN MEDICAL UNIVERSITY   (China)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID;

ARTIFICIAL VENTILATION; CORONAVIRUS DISEASE 2019; CORTICOSTEROID THERAPY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; INTENSIVE CARE UNIT; META ANALYSIS; MIDDLE EAST RESPIRATORY SYNDROME; MORTALITY RISK; PRIORITY JOURNAL; REVIEW; SEVERE ACUTE RESPIRATORY SYNDROME; SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2; SYSTEMATIC REVIEW; TREATMENT OUTCOME; BETACORONAVIRUS; CORONAVIRUS INFECTION; DRUG EFFECT; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; PANDEMIC; SARS CORONAVIRUS; VIROLOGY; VIRUS PNEUMONIA;

ADRENAL CORTEX HORMONES; BETACORONAVIRUS; CORONAVIRUS INFECTIONS; HUMANS; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; PANDEMICS; PNEUMONIA, VIRAL; SARS VIRUS; SEVERE ACUTE RESPIRATORY SYNDROME;

EID: 85084616523     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/s41375-020-0848-3     Document Type: Review

References (25)

1. Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern. Lancet. 2020;395:470–3. DOI: 10.1016/S0140-6736(20)30185-9
2. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708–20. DOI: 10.1056/NEJMoa2002032
3. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506. DOI: 10.1016/S0140-6736(20)30183-5
4. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395:507–13. DOI: 10.1016/S0140-6736(20)30211-7
5. Sung JJ, Wu A, Joynt GM, Yuen KY, Lee N, Chan PK, et al. Severe acute respiratory syndrome: report of treatment and outcome after a major outbreak. Thorax. 2004;59:414–20. DOI: 10.1136/thx.2003.014076
6. Lee N, Allen Chan KC, Hui DS, Ng EK, Wu A, Chiu RW, et al. Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients. J Clin Virol. 2004;31:304–9. DOI: 10.1016/j.jcv.2004.07.006
7. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382:727–33. DOI: 10.1056/NEJMoa2001017
8. Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020. 10.1016/S2213-2600(20)30079-5. Online ahead of print.
9. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054–62. DOI: 10.1016/S0140-6736(20)30566-3
10. Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020;e200994. 10.1001/jamainternmed.2020.0994. Online ahead of print.
11. Yam LY, Lau AC, Lai FY, Shung E, Chan J, Wong V. Corticosteroid treatment of severe acute respiratory syndrome in Hong Kong. J Infect. 2007;54:28–39. DOI: 10.1016/j.jinf.2006.01.005
12. Jia W. Retrospectivestudy of the effect of glucocorticosteroids on the treatment of severe acute respiratory syndrome 2006 [D]. Sun Yat-sen University; 2006. http://www.wanfangdata.com.cn/details/detail.do?_type=degree&id=Y1014520.
13. Wang P, Li M, Shi Y, Wang S, Liu G. Evaluating the effects of different treatments on severe acute respiratory syndrome. Shanxi Med J. 2005;34:270–2.
14. Wang G, Li N, Wu Y, Xie G, Lin J, Huang C, et al. The Cox regression analysis on the use of corticosteroids in the treatment of SARS. Natl Med J China. 2004;84:1073–78.
15. Chen RC, Tang XP, Tan SY, Liang BL, Wan ZY, Fang JQ, et al. Treatment of severe acute respiratory syndrome with glucosteroids: the Guangzhou experience. Chest. 2006;129:1441–52. DOI: 10.1378/chest.129.6.1441
16. Arabi YM, Mandourah Y, Al-Hameed F, Sindi AA, Almekhlafi GA, Hussein MA, et al. Corticosteroid therapy for critically Ill patients with Middle East respiratory syndrome. Am J Respir Crit Care Med. 2018;197:757–67. DOI: 10.1164/rccm.201706-1172OC
17. Taggart DP, D’Amico R, Altman DG. Effect of arterial revascularisation on survival: a systematic review of studies comparing bilateral and single internal mammary arteries. Lancet. 2001;358:870–5. DOI: 10.1016/S0140-6736(01)06069-X
18. Fan X, Lin T, Xu K, Yin Z, Huang H, Dong W, et al. Laparoendoscopic single-site nephrectomy compared with conventional laparoscopic nephrectomy: a systematic review and meta-analysis of comparative studies. Eur Urol. 2012;62:601–12. DOI: 10.1016/j.eururo.2012.05.055
19. Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K, et al. Diagnosis and treatment of adults with community-acquired pneumonia. an official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019;200:e45–67. DOI: 10.1164/rccm.201908-1581ST
20. Hui DSC, Zumla A. Severe acute respiratory syndrome: historical, epidemiologic, and clinical features. Infect Dis Clin North Am. 2019;33:869–89. DOI: 10.1016/j.idc.2019.07.001
21. Almaghrabi RS, Omrani AS. Middle East respiratory syndrome coronavirus (MERS-CoV) infection. Br J Hosp Med. 2017;78:23–26. DOI: 10.12968/hmed.2017.78.1.23
22. Xu X, Han M, Li T, Sun W, Wang D, Fu B, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci U S A. 2020;202005615.https://doi.org/10.1073/pnas.2005615117. Online ahead of print.
23. Rodrigo C, Leonardi-Bee J, Nguyen-Van-Tam J, Lim WS. Corticosteroids as adjunctive therapy in the treatment of influenza. Cochrane Database Syst Rev. 2016;3:Cd010406.
24. Ruan SY, Lin HH, Huang CT, Kuo PH, Wu HD, Yu CJ. Exploring the heterogeneity of effects of corticosteroids on acute respiratory distress syndrome: a systematic review and meta-analysis. Crit Care. 2014;18:R63. DOI: 10.1186/cc13819
25. Sun S, Liu D, Zhang H, Zhang X, Wan B. Effect of different doses and time-courses of corticosteroid treatment in patients with acute respiratory distress syndrome: a meta-analysis. Exp Ther Med. 2019;18:4637–44.